Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Inflammatory biomarkers in type 1 diabetes.

Frontiers in endocrinology·2026
Same author

The transcription factor AP-1 regulates the catalase family and oxidative stress adaptation in the dermatophyte Trichophyton rubrum.

Scientific reports·2026
Same author

Effect of Different Types of Whole Dietary Pulses on Established Therapeutic Lipid Targets for Cardiovascular Risk Reduction: An Updated Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.

Journal of the American Heart Association·2026
Same author

CRISPR screen uncovers SLC26A2 as a modulator of tungsten toxicity in endochondral ossification.

Environmental research·2026
Same author

Genetic Skeletal Disorders with Defects in Glycosaminoglycan Biosynthesis.

Molecular syndromology·2026
Same author

Collagen hybridizing peptide to target in vivo misfolded collagen in OI zebrafish.

Scientific reports·2026

Related Experiment Video

Updated: Mar 21, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Non-small-cell lung cancer.

Cesare Gridelli1, Antonio Rossi1, David P Carbone2

  • 1Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.

Nature Reviews. Disease Primers
|May 19, 2016
PubMed
Summary
This summary is machine-generated.

Non-small-cell lung cancer (NSCLC) is a common and deadly disease, often diagnosed late. Advances in diagnostics and targeted therapies offer improved management and quality of life for patients.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

501

Related Experiment Videos

Last Updated: Mar 21, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

501

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Diagnostics

Background:

  • Lung cancer is a leading cause of cancer death globally, with non-small-cell lung cancer (NSCLC) comprising 85% of cases.
  • Key risk factors include tobacco smoking, radon exposure, and air pollution.
  • Late diagnosis due to inadequate screening and symptoms leads to poor prognoses for most patients.

Purpose of the Study:

  • To provide a comprehensive overview of non-small-cell lung cancer (NSCLC).
  • To discuss current diagnostic approaches and staging requirements.
  • To outline evolving management strategies, including targeted therapies and palliative care.

Main Methods:

  • Review of diagnostic imaging techniques (X-ray, CT, PET) and histological examination.
  • Identification of oncogene mutations (e.g., EGFR, ALK) driving NSCLC.
  • Analysis of treatment modalities: surgery, radiochemotherapy, immunotherapy, targeted agents, and palliative care.

Main Results:

  • Accurate staging is crucial for selecting optimal treatment strategies.
  • Identification of specific mutations allows for targeted therapies, such as tyrosine kinase inhibitors.
  • Therapeutic advancements aim to overcome acquired resistance.
  • Palliative care significantly enhances patient quality of life.

Conclusions:

  • Non-small-cell lung cancer (NSCLC) requires multifaceted management strategies.
  • Early detection and precise molecular profiling are key to effective treatment.
  • Ongoing research addresses therapeutic resistance and improves patient outcomes.